The current model INCLUDES the following assets and assumptions:
The current model is based on operating metrics, including:
- Component A: Arcalyst commercial ramp in recurrent pericarditis. Full-year 2025 revenue of $681.321 million
- Component B: Risk-weighted contributions from KPL-387 in recurrent pericarditis
The current model EXCLUDES the following assets:
- KPL-1161 in recurrent pericarditis (preclinical)
-cropped.svg)
.svg){kind=small}
.svg)
.svg){kind=icon}
.svg){kind=icon}
.svg){kind=icon}
.svg)